GlassScriptPhysician profile
Igor Naryzhny
NPI 1679701239
$7,577.50
in general payments reported to CMS, 2019-2025
32 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $464 · 2021: $882 · 2022: $1,346 · 2023: $1,366 · 2024: $1,913 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,281.38 | 2019-2025 | |
| Gilead Sciences, INC. | $1,280.61 | 2019-2024 | |
| Janssen Biotech, INC. | $1,146.81 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,108.45 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $686.85 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $301.73 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $234.17 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $162.82 | 2019-2024 | Dificid |
| Genzyme Corporation | $146.32 | 2022-2024 | |
| Steris Corporation | $138.50 | 2024 | |
| Lilly USA, LLC | $133.28 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $132.79 | 2020-2024 | Linzess |
| Boston Scientific Corporation | $107.97 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $85.81 | 2024 | Voquezna |
| Pfizer INC. | $76.10 | 2019-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $63.13 | 2024 | Rebyota |
| Braintree Laboratories, INC. | $58.26 | 2022-2024 | Suflave, Sutab |
| Ethicon US, LLC | $55.79 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $54.09 | 2019-2023 | Ocaliva |
| Ardelyx, INC. | $42.32 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $35.05 | 2022 | |
| Romark Laboratories, Lc | $31.07 | 2019 | |
| Allergan, INC. | $31.00 | 2019 | |
| Evoke Pharma, INC. | $30.67 | 2022-2024 | |
| Ucb, INC. | $25.48 | 2019 | |
| Biocon Biologics INC | $21.55 | 2024 | Hulio |
| Bayer Healthcare Pharmaceuticals INC. | $20.38 | 2019 | |
| Concordia Pharmaceuticals INC. | $19.09 | 2019 | |
| Daiichi Sankyo INC. | $18.88 | 2019 | |
| Shionogi INC | $18.21 | 2020 | |
| Vivus LLC | $15.77 | 2023 | Qsymia |
| W. L. Gore & Associates, INC. | $13.17 | 2023 | Gore Cardioform Septal Occluder |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Naryzhny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.